Travere Therapeutics Inc. (TVTX)
NASDAQ: TVTX
· Real-Time Price · USD
15.85
0.15 (0.96%)
At close: May 23, 2025, 3:59 PM
16.02
1.10%
After-hours: May 23, 2025, 07:10 PM EDT
0.96% (1D)
| Bid | 15.77 |
| Market Cap | 1.41B |
| Revenue (ttm) | 273.53M |
| Net Income (ttm) | -226.71M |
| EPS (ttm) | -2.78 |
| PE Ratio (ttm) | -5.7 |
| Forward PE | 23.07 |
| Analyst | Buy |
| Ask | 16.04 |
| Volume | 1,058,412 |
| Avg. Volume (20D) | 1,802,312 |
| Open | 15.57 |
| Previous Close | 15.70 |
| Day's Range | 15.49 - 16.13 |
| 52-Week Range | 6.14 - 25.29 |
| Beta | 0.88 |
About TVTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TVTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TVTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-20.57%
Travere Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
1 week ago
+0.28%
Travere Therapeutics shares are trading lower. The company announced that the FDA accepted its supplemental New Drug Application for traditional approval of FILSPARI for the treatment of focal segmental glomerulosclerosis.
2 weeks ago · businesswire.com
Travere Therapeutics to Participate at Upcoming Investor ConferencesSAN DIEGO--(BUSINESS WIRE)-- #Inrareforlife--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Sec...
3 weeks ago · seekingalpha.com
Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call TranscriptTravere Therapeutics, Inc. (NASDAQ:TVTX ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO J...